# Quality ID #66: Appropriate Testing for Children with Pharyngitis

- National Quality Strategy Domain: Efficiency and Cost Reduction
- Meaningful Measure Area: Appropriate Use of Healthcare

#### **2020 COLLECTION TYPE:**

MIPS CLINICAL QUALITY MEASURES (CQMS)

#### **MEASURE TYPE:**

Process – High Priority

#### **DESCRIPTION:**

Percentage of children 3-18 years of age who were diagnosed with pharyngitis, ordered an antibiotic and received a group A streptococcus (strep) test for the episode

# **INSTRUCTIONS:**

This measure is to be submitted once for <u>each occurrence</u> of pharyngitis during the performance period. Claims data will be analyzed to determine unique occurrences. This measure is intended to reflect the quality of services provided for the primary management of patients with pharyngitis who were dispensed an antibiotic. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

#### **Measure Submission Type:**

Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

# **DENOMINATOR:**

Children 3 - 18 years of age who had an outpatient or emergency department (ED) visit with a diagnosis of pharyngitis during the measurement period and an antibiotic ordered on or three days after the visit

#### **Denominator Instruction:**

To determine eligibility, look for any of the listed antibiotic drugs below in the 30 days prior to the visit with the pharyngitis diagnosis. As long as there are no prescriptions for the listed antibiotics during this time period, the patient is eligible for denominator inclusion.

**DENOMINATOR NOTE:** \*Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for MIPS CQMs.

# <u>Denominator Criteria (Eligible Cases):</u>

Patients aged 3 to 18 years on date of encounter

#### AND

**Diagnosis for pharyngitis (ICD-10-CM):** J02.0, J02.8, J02.9, J03.00, J03.01, J03.80, J03.81, J03.90, J03.91

#### AND

Patient encounter during the performance period (CPT or HCPCS): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99217, 99218, 99219, 99220, 99241\*, 99242\*, 99243\*, 99244\*, 99245\*, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99401\*, 99402\*, 99403\*, 99404\*, 99411\*, 99412\*, 99429\*, 99455, 99456, 99281, 99282, 99283, 99284, 99285, 99381\*, 99382\*, 99383\*, 99384\*, 99385\*, 99386\*, 99387\*, 99391\*, 99392\*, 99393\*, 99394\*, 99395\*, 99396\*, 99397\*

and

Prescribed or dispensed antibiotic: G8711

AND NOT

# **DENOMINATOR EXCLUSIONS:**

Patients who use hospice services any time during the measurement period: G9702

<u>OR</u>

Children who are taking antibiotics in the 30 days prior to the diagnosis of pharyngitis: G9703

OR

Children with a competing diagnosis for Upper Respiratory Infection within three days of diagnosis of pharyngitis

**Table 1 - Antibiotic Medications** 

Description	Prescription
Aminopenicillins	Amoxicillin
	Ampicillin
Beta-lactamase inhibitors	Amoxicillin clavulanate
First generation cephalosporins	Cefadroxil
	Cephalexin
	Cefazolin
Folate antagonist	Trimethoprim
Lincomycin derivatives	Clindamycin
Macrolides	Azithromycin
	Erythromycin ethylsuccinate
	Clarithromycin
	Erythromycin lactobionate
	Erythromycin
	Erythromycin stearate
Miscellaneous antibiotics	Erythromycin-sulfisoxazole
Natural penicillins	Penicillin G potassium
	Penicillin V potassium
	Penicillin G sodium
Penicillinase-resistant penicillins	Dicloxacillin
Quinolones	Ciprofloxacin
	Moxifloxacin
	Levofloxacin
	Ofloxacin
Second generation cephalosporins	Cefaclor
	Cefuroxime
	Cefprozil
Sulfonamides	Sulfamethoxazole-trimethoprim
Tetracyclines	Doxycycline
	Tetracycline
	Minocycline

Description	Prescription
Third generation cephalosporins	Cefdinir Ceftibuten Cefixime Cefditoren Cefpodoxime
	Ceftriaxone

#### **NUMERATOR:**

Children with a group A streptococcus test in the 7-day period from 3 days prior through 3 days after the diagnosis of pharyngitis

#### **Numerator Instruction:**

A higher score indicates appropriate treatment of children with pharyngitis (e.g., the proportion for whom antibiotics were prescribed with an accompanying step test).

**Numerator Options:** 

Performance Met: Group A Strep Test Performed (3210F)

<u>OR</u>

Performance Not Met: Group A Strep Test not Performed, reason not

otherwise specified (3210F with 8P)

# **RATIONALE:**

Group A streptococcal bacterial infections and other infections that cause pharyngitis (which are most often viral) often produce the same signs and symptoms (Shulman et al., 2012). The American Academy of Pediatrics, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America all recommend a diagnostic test for Strep A to improve diagnostic accuracy and avoid unnecessary antibiotic treatment (Linder et al. 2005).

Estimated economic costs of pediatric streptococcal pharyngitis in the United States range from \$224 million to \$539 million per year, including indirect costs related to parental work losses. At a higher level, the economic cost of antibiotic resistance vary but have extended as high as \$20 billion in excess direct healthcare costs, with additional costs to society for lost productivity as high as \$35 billion a year (2008 dollars) (Roberts et al. 2009).

#### **CLINICAL RECOMMENDATION STATEMENTS:**

Infectious Disease Society of America (2012)

The Infectious Diseases Society of America (IDSA) "recommends swabbing the throat and testing for GAS pharyngitis by rapid antigen detection test (RADT) and/or culture because the clinical features alone do not reliably discriminate between GAS and viral pharyngitis except when overt viral features like rhinorrhea, cough, oral ulcers, and/or hoarseness are present"

#### **COPYRIGHT:**

Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA). These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. NCQA makes no representations, warranties or endorsements about the quality of any organization or clinician who uses or reports performance measures. NCQA has no liability to anyone who relies on measures and specifications or data reflective of performance under such measures and specifications.

The Measures are copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (eg, use by healthcare providers in connection with their practices). Commercial use is defined as the sale, licensing, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. All commercial uses or requests for alteration of the measures and specifications must be approved by NCQA and are subject to a license at the discretion of NCQA. NCQA is not responsible for any use of the Measures. © 2019 NCQA. All Rights Reserved.


THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any CPT or other codes contained in the specifications.

CPT® contained in the Measure specifications is copyright 2004-2019 American Medical Association. LOINC® copyright 2004-2019 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms® (SNOMED CT®) copyright 2004-2019 International Health Terminology Standards Development Organisation. ICD-10 copyright 2019 World Health Organization. All Rights Reserved.

# 2020 Clinical Quality Measure Flow for Quality ID #66: Appropriate Testing for Children with Pharyngitis

Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.



# SAMPLE CALCULATIONS: Data Completeness = Performance Met (a=50 episodes) + Performance Not Met (o=20 episodes) = 70 episodes = 87.50% Eligible Population / Denominator (d=80 episodes) = 80 episodes Performance Rate = Performance Met (a=50 episodes) = 50 episodes = 71.43% Data Completeness Numerator (70 episodes) = 70 episodes

CPT only copyright 2019 American Medical Association. All rights reserved. The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.

<sup>\*</sup> See the posted measure specification for specific coding and instructions to submit this measure. NOTE: Submission Frequency: Episode

# 2020 Clinical Quality Measure Flow Narrative for Quality ID #66: Appropriate Testing for Children with Pharyngitis

**Disclaimer:** Refer to the measure specification for specific coding and instructions to submit this measure.

- 1. Start with Denominator
- 2. Check Patient Age:
  - a. If Patients Aged 3 to 18 Years on Date of Encounter equals No during the measurement period, do not include in Eligible Population. Stop Processing.
  - b. If Patients Aged 3 to 18 Years on Date of Encounter equals Yes during the measurement period, proceed to check Patient Diagnosis.
- 3. Check Patient Diagnosis:
  - a. If Diagnosis of Pharyngitis as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
  - b. If Diagnosis of Pharyngitis as Listed in the Denominator equals Yes, proceed to check Encounter Performed.
- 4. Check Encounter Performed:
  - a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
  - b. If Encounter as Listed in the Denominator equals Yes, proceed to check Antibiotic Prescribed or Dispensed.
- 5. Check Antibiotic Prescribed or Dispensed:
  - a. If Antibiotic Prescribed or Dispensed equals No, do not include in Eligible Population. Stop Processing.
  - b. If Antibiotic Prescribed or Dispensed equals Yes, proceed to check Patients Who Use Hospice Services Any Time During the Measurement Period.
- 6. Check Patients Who Use Hospice Services Any Time During the Measurement Period:
  - a. If Patients Who Use Hospice Services Any Time During the Measurement Period equals Yes, do not include in Eligible Population. Stop Processing.
  - b. If Patients Who Use Hospice Services Any Time During the Measurement Period equals No, proceed to check Children Who Are Taking Antibiotics in the 30 Days Prior to the Diagnosis of Pharyngitis.

- 7. Check Children Who Are Taking Antibiotics in the 30 Days Prior to the Diagnosis of Pharyngitis:
  - a. If Children Who Are Taking Antibiotics in the 30 Days Prior to the Diagnosis of Pharyngitis equals Yes, do not include in Eligible Population. Stop Processing.
  - b. If Children Who Are Taking Antibiotics in the 30 Days Prior to the Diagnosis of Pharyngitis equals No, proceed to check Children With a Competing Diagnosis for Upper Respiratory Infection within Three Days of Diagnosis of Pharyngitis.
- 8. Check Children With a Competing Diagnosis for Upper Respiratory Infection within Three Days of Diagnosis of Pharyngitis:
  - a. If Children With a Competing Diagnosis for Upper Respiratory Infection within Three Days of Diagnosis of Pharyngitis Yes, do not include in Eligible Population. Stop Processing.
  - b. If Children With a Competing Diagnosis for Upper Respiratory Infection within Three Days of Diagnosis of Pharyngitis equals No, include in Eligible Population.

#### 9. Denominator Population:

a. Denominator Population is all Eligible Episodes in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 episodes in the Sample Calculation.

#### 10. Start Numerator

- 11. Check Group A Streptococcus Test Performed:
  - a. If Group A Streptococcus Test Performed equals Yes, include in Data Completeness Met and Performance Met.
  - b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 50 episodes in the Sample Calculation.
  - c. If Group A Streptococcus Test Performed equals No, proceed to check Group A Streptococcus Test Not Performed, Reason Not Otherwise Specified.
- 12. Check Group A Streptococcus Test Not Performed, Reason Not Otherwise Specified:
  - a. If Group A Streptococcus Test Not Performed, Reason Not Otherwise Specified equals Yes, include in Data Completeness Met and Performance Not Met.
  - b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 20 episodes in the Sample Calculation.
  - c. If Group A Streptococcus Test Not Performed, Reason Not Otherwise Specified equals No, proceed to check Data Completeness Not Met.
- 13. Check Data Completeness Not Met:
- a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 episodes

  Version 4.1 CPT only copyright 2019 American Medical Association. All rights reserved.

  January 2020 Page 7 of 8

have been subtracted from the Data Completeness Numerator in the Sample Calculation.

# **SAMPLE CALCULATIONS:**

Data Completeness=
Performance Met (a=50 episodes) + Performance Not Met (c=20 episodes) = 70 episodes = 87.50%
Eligible Population / Denominator (d=80 episodes) = 80 episodes

Performance Met(a=50 episodes) = 50 episodes = 71.43 %

Data Completeness Numerator (70 episodes) = 70 episodes